Jun 2026 (Q2 FY26) — Jul 28, 2026
Kiniksa Pharmaceuticals Q2 FY26 — Strong ARCALYST Growth and KPL-387 Phase III Initiation
Read the full callKiniksa Pharmaceuticals (KNSA) earnings
- Mar 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Kiniksa Pharmaceuticals earnings: last reported Tue, 28 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 214 | +55.5% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | 13.7 | +4.0 pts YoY | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. |
| Net profit | 22.6 | +164.6% YoY | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. |
Price
$79.48 +1.13% · +$0.89
Performance +105.7% 1Y
1Y: $38.64 on 17 Oct 2025 → $79.48. High $80.92 (29 Jul 2026), low $37.01 (31 Oct 2025).
- Previous close
- $78.59
- 52-week range
- $37.01 – $80.92
- One year
- +103.85%
Overview
- Symbol
- KNSA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Apr 28, 2026
Kiniksa Q1 FY26 — ARCALYST Revenue Growth and Pipeline Advancement
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Kiniksa Pharmaceuticals Q4 FY25 — ARCALYST Drives Strong Revenue Growth and Profitability, Pipeline Advances
Read the full callEvery analysed call
Kiniksa Pharmaceuticals earnings calls (KNSA)
Financials
What the filings say
Net profit, year on year: +165% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 112 | 123 | 138 | 157 | 181 | 202 | 214 |
| Operating profit | -0 | -10 | -19 | 13 | 20 | 24 | 20 | 29 |
| Operating margin | −0.1% | −8.6% | −15.8% | 9.6% | 12.9% | 13.3% | 9.8% | 13.7% |
| Profit before tax | 2 | -7 | -17 | 16 | 23 | 27 | 23 | 33 |
| Tax rate | 269.6% | −76.3% | 47.6% | 45.1% | 22.1% | 32.1% | 39.0% | 30.9% |
| Net profit | -4 | -13 | -9 | 9 | 18 | 18 | 14 | 23 |
| EPS ($ per share) | -0.06 | -0.18 | — | 0.12 | 0.24 | 0.25 | — | 0.30 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Reserves | -194 | -356 | -517 | -675 | -492 | -478 | -521 | -462 |
| Total liabilities | 43 | 29 | 38 | 48 | 64 | 87 | 142 | 196 |
| Fixed assets | 6 | 6 | 4 | 3 | 2 | 1 | 1 | 2 |
| Investments | 235 | 186 | 209 | 60 | 68 | 98 | 60 | 248 |
| Total assets | 322 | 255 | 349 | 233 | 460 | 526 | 581 | 764 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -81 | -158 | -137 | -126 | 6 | 13 | 26 | 138 |
| Cash from investing | -239 | 49 | -23 | 129 | -8 | -30 | 38 | -189 |
| Cash from financing | 347 | 84 | 227 | 6 | 3 | 1 | 12 | 33 |
| Capital expenditure | -5 | -3 | -0 | -0 | -0 | -0 | -0 | -2 |
| Free cash flow | -86 | -162 | -137 | -127 | 6 | 13 | 25 | 136 |
KNSA revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +55.4% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
KNSA operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Prescribers | 4,150+At the end of 2025, more than 4,150 prescribers had written a prescription for ARCALYST.Source: earnings call transcript | — | 5,000+Approximately 450 additional health care professionals wrote their first ARCALYST prescription in the second quarter, bringing the total prescriber base to more than 5,000 launch to date.Source: earnings call transcript | — |
| Repeat prescribers | 1,200+Of those, around 29% or more than 1,200 prescribers have written ARCALYST for 2 or more recurrent pericarditis patients.Source: earnings call transcript | ~1,320We also saw growth in the number of health care professionals who became repeat prescribers during Q1, resulting in approximately 1,320 prescribers in total who have now prescribed ARCALYST multiple times.Source: earnings call transcript | — | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Revenue by region
Q2 FY2026 · share of revenue
- US 100%
- GB <1%
As KNSA cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
160 filings between Oct 20, 2025 and Sep 3, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$59.82M
45 sales by 8 insiders
98% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 6
- Award — granted as compensation
- 84
- Option exercise — converted options into shares
- 18
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 gifts, 1 conversion.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Patel Sanj K | — | $39.43M | May 1, 2026 |
| Paolini John F. | — | $8.00M | May 1, 2026 |
| Ragosa Mark | — | $5.56M | Mar 9, 2026 |
| Quart Barry D | — | $2.68M | Apr 28, 2026 |
| Megna Michael R | — | $2.64M | Sep 3, 2026 |
| Tessari Eben | — | $1.02M | Dec 15, 2025 |
| Cole G Bradley | — | $299.1K | Jul 29, 2026 |
| Moat Ross | — | $194.5K | Apr 9, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Sale 10b5-1 plan | 4,600 | $369.4K |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 9,991 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 6,237 | — |
| Sep 1, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 plan | 2,362 | — |
| Sep 1, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 plan | 3,932 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Tax withheld | 15,144 | $1.20M |
| Sep 1, 2026 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise | 2,694 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 6,237 | — |
| Sep 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Tax withheld | 4,029 | $319.4K |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 9,991 | — |
| Sep 1, 2026 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise | 1,750 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 6,481 | — |
| Sep 1, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Tax withheld 10b5-1 plan | 5,531 | $438.5K |
| Sep 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise | 1,624 | — |
| Sep 1, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 plan | 2,644 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 6,481 | — |
| Sep 1, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 plan | 2,558 | — |
| Sep 1, 2026 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise | 1,591 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 8,609 | — |
| Sep 1, 2026 | Moat Ross CHIEF OPERATING OFFICER | Tax withheld | 4,007 | $317.7K |
| Sep 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise | 2,457 | — |
| Sep 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise | 1,750 | — |
| Sep 1, 2026 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | 2,457 | — |
| Sep 1, 2026 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | 1,611 | — |
| Sep 1, 2026 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | 2,477 | — |
| Sep 1, 2026 | Ragosa Mark CHIEF FINANCIAL OFFICER | Tax withheld | 4,404 | $349.1K |
| Sep 1, 2026 | Ragosa Mark CHIEF FINANCIAL OFFICER | Option exercise | 3,069 | — |
| Sep 1, 2026 | Moat Ross CHIEF OPERATING OFFICER | Option exercise | 1,740 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise | 8,609 | — |
| Sep 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise | 2,497 | — |
| Sep 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Tax withheld | 15,144 | $1.20M |
| Aug 19, 2026 | Quart Barry D Director | Gift | 2,600 | $0 |
| Aug 1, 2026 | Levy Richard S Director | Option exercise | 403 | — |
| Jul 29, 2026 | Cole G Bradley Director | Gift | 4,500 | $0 |
| Jul 29, 2026 | Cole G Bradley Director | Sale | 3,673 | $299.1K |
| Jul 15, 2026 | Megna Michael R CHIEF ACCOUNTING OFFICER | Award 10b5-1 plan | 279 | $9.3K |
| Jun 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Conversion | 900,000 | — |
| May 29, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,078 | $0 |
| May 29, 2026 | BAKER BROS. ADVISORS LP Director | Award | 6,078 | $0 |
| May 29, 2026 | Popovits Kimberly J Director | Option exercise | 2,799 | — |
| May 29, 2026 | McCain Tracey L Director | Option exercise | 2,799 | — |
| May 29, 2026 | Levy Richard S Director | Option exercise | 2,799 | — |
| May 29, 2026 | Malley Thomas Director | Option exercise | 2,799 | — |
| May 29, 2026 | Quart Barry D Director | Option exercise | 2,799 | — |
| May 29, 2026 | Cole G Bradley Director | Option exercise | 2,799 | — |
| May 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 37,327 | $2.00M |
| May 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Sale 10b5-1 plan | 21,097 | $1.14M |
| May 1, 2026 | Paolini John F. CHIEF MEDICAL OFFICER | Option exercise 10b5-1 plan | 58,424 | $605.3K |
| May 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Option exercise 10b5-1 plan | 48,565 | $1.50M |
| May 1, 2026 | Patel Sanj K CHAIRMAN & CEO | Sale 10b5-1 plan | 48,565 | $2.62M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Kiniksa Pharmaceuticals International, plc
Free account. Everything above stays public.
Write why you follow Kiniksa Pharmaceuticals International, plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading